Table 3.
Adverse drug reactions which occurred in > 30% of patients in group A (n = 53) (any grade and grade ≥ 3)
| Group A | Group B | |||||
|---|---|---|---|---|---|---|
| Any grade | Grade 3 | Grade 4 | Any grade | Grade 3 | Grade 4 | |
| Hematological toxicities | ||||||
| Neutropenia | 53 (100.0) | 9 (17.0) | 43 (81.1) | 5 (100.0) | 1 (20) | 3 (60) |
| Leucopenia | 53 (100.0) | 30 (56.6) | 16 (30.2) | 5 (100.0) | 3 (60) | |
| Lymphocytopenia | 42 (79.2) | 14 (26.4) | 1 (1.9) | 3 (60.0) | 2 (40) | |
| Hemoglobin decreased | 39 (73.6) | 2 (3.8) | 1 (1.9) | 3 (60.0) | ||
| Thrombocytopenia | 34 (64.2) | 5 (9.4) | 4 (7.5) | 2 (40.0) | ||
| Non-hematological toxicities | ||||||
| Alopecia | 51 (96.2) | 5 (100.0) | ||||
| Decreased appetite | 45 (84.9) | 8 (15.1) | 3 (60.0) | 1 (20.0) | ||
| Fatigue | 44 (83.0) | 8 (15.1) | 3 (60.0) | |||
| Diarrhea | 35 (66.0) | 3 (5.7) | 2 (40.0) | |||
| Nausea | 33 (62.3) | 2 (3.8) | 4 (80.0) | 1 (20.0) | ||
| Blood albumin decreased | 26 (49.1) | 1 (1.9) | 3 (60.0) | |||
| Alanine aminotransferase increased | 23 (43.4) | 1 (1.9) | ||||
| Gamma-glutamyltransferase increased | 22 (41.5) | 7 (13.2) | ||||
| Aspartate aminotransferase increased | 18 (34.0) | 2 (3.8) | ||||
Data are expressed as n (%)
Treatment-related adverse events